helps majorly," he said in a report. In other acquisition news, Eli Lilly announced its plan to buy a drug called STX-478 from privately held Scorpion Therapeutics. The drug blocks PI3Ka ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...